Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Jul 20;12:677169. doi: 10.3389/fimmu.2021.677169

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2021 Liu, Wang, Li, Qu, Xue, Ma, Zhang, Bai and Wang

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

Overexpression of ERO1L predicts resistance to immunotherapy. (A) Boxplot showing stromal, immune, and Estimate scores within ERO1L ^high and ERO1L ^low groups. (B, C) Prediction of immunotherapy response using the TIDE computational framework. Other biomarkers for immunotherapy were also assessed. These included: IFN-γ, MSI signatures, PD-L1, MDSCs, CAFs, and TAM-M2. (D) Violin plot showing MDSCs, CD8⁺ T, and dysfunction scores within the ERO1L ^high and ERO1L ^low groups. Groups are labeled in different colors according to their level of ERO1L expression.